Healthcare
Yubo International Biotech Limited(YBGJ)
Live Price
Offline$0.007
+0.00% today
1Y Change
-90.27%
Window
Jun 23, 2025 โ Jun 15, 2026
- Market Cap
- โ
- Revenue Growth
- +3772.9%
- EPS Growth
- +32.4%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 23, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Yubo International Biotech Limited (YBGJ) is a Healthcare stock with listed on OTC. The stock last traded around $0.01 and down 90.3% across the available one-year price window (Jun 23, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +3772.9%, EPS growth of +32.4%, a dividend yield of 0.0%. What stands out right now is revenue +3772.9%, EPS +32.4%, free cash flow +37.0% with operating margin -883.8% and ROIC 57.8%. Valuation sits in the middle of the pack at price/sales 7.5. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines YBGJ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+3772.9% vs +7.6% peer median
Operating Margin
Below sector median
-883.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 15, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +3772.9% and EPS at +32.4%, with operating margin around -883.8%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -12.7% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 15, 2026 | โ | +0.0% | +0.0% | +0.0% |
2026 Mar 31, 2026 | โ | +0.0% | -37.1% | -44.4% |
2025 Nov 14, 2025 | โ | +0.0% | -1.1% | -6.7% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
YBGJ
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
YBGJ Max Drawdown
-94.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for YBGJ and SPY.
Company Overview
Yubo International Biotech Limited
Other OTC
Yubo International Biotech Limited, thorough its subsidiaries, focuses on the research and development, and application of endometrial stem cells. It offers healthcare products for respiratory system, skincare products, hair care products, healthy beverages, and male and female personal care products; and stem cell related services, including cell testing and health management consulting services under the VIVCELL brand. The company is based in Beijing, China.
- Leadership
- Yang Wang
- IPO Date
- Aug 24, 2021
- Employees
- 18
- Street Address
- Building 5
- Mailing
- Beijing
- Region
- Beijing, CN
- Reporting Currency
- USD
- Investor Line
- 86 10 6615 5141
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 7.5
- Price/Book
- โ
Growth
- Revenue
- +3772.9%
- EPS
- +32.4%
- Free Cash Flow
- +37.0%
Profitability
- Gross Margin
- 6.1%
- Operating Margin
- -883.8%
- Net Margin
- -803.1%
- ROE
- 38.2%
- ROIC
- 57.8%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.24
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.